Avoidance of Aβ[25-35]/(H2O2)-induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanism: Role of NF-κB and p53

Medicinal Chemistry

Volumn 2, Issue 5, 2006, Pages 471-479

  Velez Pardo, C ^a   Jimenez Del Rio, M ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Beta amyloid; CP55,940; JWH 015; NF B; p53; PI 3K

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AMYLOID BETA PROTEIN[25-35]; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIFITHRIN ALPHA; PROTEIN P53; RHODAMINE 123; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (25 35); AMYLOID BETA-PROTEIN (25-35); CANNABINOID; CANNABINOID RECEPTOR; CYCLOHEXANE DERIVATIVE; INDOLE DERIVATIVE; JHW 015; PEPTIDE FRAGMENT; PHENOL DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; NEUROPROTECTION; OXIDATION; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; CELL PROTECTION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; LYMPHOCYTE; METABOLISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AMYLOID BETA-PROTEIN; APOPTOSIS; CANNABINOIDS; CYCLOHEXANES; CYTOPROTECTION; HUMANS; HYDROGEN PEROXIDE; INDOLES; LYMPHOCYTES; MALE; NF-KAPPA B; PEPTIDE FRAGMENTS; PHENOLS; PROTEIN KINASE INHIBITORS; RECEPTORS, CANNABINOID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748681306     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340606778250171     Document Type: Article

References (57)

1. ElSohly, M.A.; Slade, D. Life Sci., 2005, 78, 539.
2. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.; Young, A.; Bonner, T.I. Nature (London), 1990, 346, 561.
3. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Nature (London), 1993, 365, 61.
4. Demuth, D. G.; Molleman, A. Life Sci., 2006, 78, 549.
5. Pazos, M.R.; Nuñez, E.; Benito, C.; Tolon, R.M.; Romero, J. Pharmacol. Biochem. Behaviour, 2005, 81, 239.
6. Skaper, S.D.; Buriani , A.; Dal Toso, R.; Petrelli, L.; Romanello, S.; Facci, L.; Leon A. Proc. Natl. Acad. Sci. USA, 1996, 93, 3984.
7. Klegeris, A.; Bissonnette, C.J.; McGeer, P.L. Br. J. Pharmacol., 2003, 139, 775.
8. Molina-Holgado, E.; Vela, J.M.; Arevalo-Martin, A.; Almazan, G.; Molina-Holgado, F.; Borrell, J.; Guaza, C. J. Neurosci., 2002, 22, 9742.
9. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marno, V.; Pittman, Q.J.; Patel, K.D. Science, 2005, 310, 329.
10. Gomez Del Pulgar, T.; Velasco, G.; Guzman, M. Biochem. J., 2000, 347, 369.
11. Gomez Del Pulgar, T.; de Ceballos, M.L.; Guzman, M.; Velasco, G. J. Biol. Chem., 2002, 277, 36527.
12. Sanchez, M.G.; Ruiz-Llorente, L.; Sanchez, A.M.; Diaz-Leviada, I. Cell Signal., 2003, 15, 851.
13. Guzman, M. Br. J. Pharmacol., 2003, 140, 439.
14. Hampson, A.J; Grimaldi, M.; Axelrod, J.; Wink, D. Proc. Natl. Acad. Sci. USA, 1998, 95, 8268.
15. Chen, Y.; Buck, J. J. Pharmacol. Exp. Ther., 2000, 293, 807.
16. Marsicano, G.; Moosmann, B.; Hermann, H.; Lutz, B.; Behl, C. J. Neurochem., 2002, 80, 448.
17. Nagayama, T.; Sinor, A.D.; Simon, R.P.; Chen, J.; Graham, S.H.; Jin, K.; Greenberg, D.A. J. Neurosci., 1999, 19, 2987.
18. Kim, S.H.; Won, S.J.; Mao, X.O.; Jin, K.; Greenberg, D.A. J. Pharmacol Exp Ther 2005 31388
19. Esiri, M.M. In: Neurobiology of Alzheimer's disease. Dawbarn, D.; Allen, S.J.; Eds.; Oxford University Press:, 2001; pp. 33-53.
20. Cotman, C.W.; Tong, L.; Anderson, A.; Cribbs, D.; Su, J. In: Alzheimer's disease. Advances in etiology, pathogenesis and therapeutics. Iqbal, K.; Sisodia, S.S.; Winblad, B.; Eds.; John Wiley & Sons Ltd: New York, 2001, pp. 407-420.
21. Butterfield, D.A.; Boyd-Kimball, D. Brain Pathol., 2004, 14, 426.
22. McLellan, M.E.; Kajdasz, S.T.; Imán, B.T.; Bacskai, B.J. J. Neurosci., 2003, 23, 2212.
23. Garcia-Ospina, G.; Jimenez Del Rio, M.; Lopera, F.; Velez-Pardo, C. Rev. Neurol., 2003, 36, 1004.
24. Velez-Pardo, C.; Garcia-Ospina, G.; Jimenez Del Rio, M. Neuro-Toxicology, 2002, 23, 351.
25. Marino, F.; Cosentino, M.; Bombelli, R.; Ferrari, M.; Lecchini, S.; Frigo, G. Exp. Hematol., 1999, 27, 489.
26. Gordon, J.; Barnes, N.M. Trends Immunol., 2003; 24, 438.
27. Kawashima, K.; Fujji, T. Pharmacol. Therap., 2000, 86, 29.
28. Lombardi,G.; Dianzani, C.; Miglio, G.; Canonico, P.L.; Fantozzi, R. Br. J. Pharmacol., 2001;133,936.
29. Miglio, G.; Varsaldi, F.; Dianzani, C.; Fantozzi, R.; Lombardi, G. Biochem. Pharmacol., 2005, 70, 189.
30. Sanders, V.M. Adv. Exp. Med. Biol., 1998,437,269.
31. Tillakaratne, N.J.; Medina-Kauwe, L.; Gibson, K.M. comp. Biochem. Physiol. A. Physiol., 1995,112,247.
32. Jimenez Del Rio, M.; Velez-Pardo, C. Curr. Med. Chem.-CNS Agents, 2004, 4, 279.
33. Ramírez, B.G.; Blázquez, C.; Gomez Del Pulgar, T.; Guzmán, M.; de Ceballos, M.L. J. Neurosci., 2005, 25, 1904.
34. Thomas, B.F.; Gillliam, A.F.; Burch, D.F.; Roche, M.J.; Seltzman, H.H. J. Pharmacol. Exp. Ther., 1998,285, 285.
35. Leite, M.; Quinta-Costa, M.; Leite, P.S.; Guimaraes, J.E. Anal. Cell Pathol., 1999, 19(3-4), 139.
36. Rothe, G.; Valet, G. Methods Enzymol., 1994, 233, 539.
37. Iuvone, T.; Esposito, G.; Esposito, R.; Santamaría, R.; Di, Rosa; M., Izzo, A.A. J. Neurochem., 2004, 89, 134.
38. Song, G.; Ouyang, G.; Bao, S. J. Cell Mol. Med., 2005, 9, 59.
39. Kane, L.P.; Shapiro, V.S.; Stokoe, D.; Weiss, A. Curr. Biol., 1999, 9, 601.
40. Molina-Holgado, F.; Pinteaux, E.; Heenan, L.; Moore, J.D.; Rothwell, N.J.; Gibson, RM. Mol Cell Neurosci., 2005,28,189.
41. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A.J. Lancet Neurol., 2003, 2, 291.
42. Ramos, J.A.; Gonzalez, S.; Sagrado, O.; Gomez-Ruiz, M.; Fernandez-Ruiz, J.; Mini Rev. Med. Chem., 2005, 5,609.
43. Wu, H.; Lozano, G. J. Biol. Chem., 1994, 269, 20067.
44. Hellin, A.C.; Calmant, P.; Gielen, J.; Bours, V.; Merville, M.P. Oncogene, 1998, 16, 1187.
45. Jimenez Del Rio, M.; Velez-Pardo, C. Biochem. Pharmacol., 2002, 63, 677.
46. Miyashita, T.; Reed, J.C. Cell, 1995, 80, 293.
47. Deng, Y.; Wu, X. Proc. Natl. Acad. Sci. USA, 2000, 97, 12050.
48. Cory, S.; Adams, J.M. Cancer Cell,2005, 8, 5.
49. Ogawara, Y.; Kishishita, S.; Obata, T.; Isazawa, Y.; Suzuki, T.; Tanaka, K.; Masuyama, N.; Gotoh, Y. J. Biol. Chem., 2002, 277, 21843.
50. Feng, J., Tamaskovic, R.; Yang, Z.; Brazil D.P.; Merlo, A.; Hes, D.; Hemmings, B.A. J. Biol. Chem., 2004, 279, 35510.
51. Yu, J.; Zhang, L. Biochem. Biophysic. Res. Commu., 2005, 331, 851.
52. Benito, C.; Núñez, E.; Tolon, R.M.; Carrier, E. J.; Rabano, A.; Hillard, C.J.; Romero J. J. Neurosci., 2003, 23, 11136.
53. Behl, C.; Davis, J.B.; Lesley, R.; Schubert,D. Cell, 1994, 77, 817.
54. Milton, N.G.N. Drugs Aging, 2004, 21, 81.
55. Viña, J.; Iloret, A.; Orti, R.; Alonso, D. Mol. Aspects Med., 2004, 25, 117.
56. Grundy, R.I. Expert Opin. Investig. Drugs, 2002, 11, 1365.
57. Sarne, Y.; Keren, O. Med. Hypotheses, 2004, 63, 187.